Clinical Trials
71 trialsIberdomide Alone or in Combination With Dexamethasone for the Treatment of Intermediate- or High-Risk Smoldering Multiple Myeloma
Emory University
Curcumin and Piperine in Patients on Surveillance for Monoclonal Gammopathy, Smoldering Myeloma or Prostate Cancer
University of Rochester
Study of MGUS, Smoldering Myeloma, Early MDS and CLL to Assess Molecular Events of Progression and Clinical Outcome
Dana-Farber Cancer Institute
Questionnaire and Tissue Banking For Multiple Myeloma, Waldenstrom Macroglobulinemia and Related Disorders
Dana-Farber Cancer Institute
FAST-M
University of Miami
Leflunomide for the Treatment of High-Risk Smoldering Multiple Myeloma in African-American and European-American Patients
City of Hope Medical Center
Observational Prospective Research Study In Monoclonal Gammopathies leadINg to Myeloma
M.D. Anderson Cancer Center
A Study Comparing a Plant-Based Diet With Supplements and Placebo in People With Monoclonal Gammopathy of Undetermined Significance (MGUS) or Smoldering Multiple Myeloma (SMM)
Memorial Sloan Kettering Cancer Center
ProDigALIty
Fondazione IRCCS Policlinico San Matteo di Pavia
Isatuximab With or Without Lenalidomide in Patients With High Risk Smoldering Multiple Myeloma (ISAMAR)
M.D. Anderson Cancer Center
Quality of Life in Patients With Asymptomatic Monoclonal Gammopathies
M.D. Anderson Cancer Center
TRANSFORMM
University of Miami
HiFi-MM
IRCCS San Raffaele
Phase II Study of the CD38 Antibody Daratumumab in Patients With High-Risk MGUS and Low-Risk Smoldering Multiple Myeloma
Dana-Farber Cancer Institute
Evaluating the Impact of a 12-month Multi-Modal Lifestyle Management Intervention on Disease Relevant Biomarkers
Hackensack Meridian Health
A Study of PVX-410, a Cancer Vaccine, and Citarinostat +/- Lenalidomide for Smoldering MM
Massachusetts General Hospital
CAR- PRISM (PRecision Intervention Smoldering Myeloma)
Dana-Farber Cancer Institute
SPOTLIGHT
University of Utah
Investigation of Metformin for the Prevention of Progression of Precursor Multiple Myeloma
Dana-Farber Cancer Institute
Pembrolizumab in Treating Patients With Intermediate or High-Risk Smoldering Multiple Myeloma
M.D. Anderson Cancer Center
Denosumab for Smoldering Multiple Myeloma
University of Rochester
KORMED-PA Stud
Seoul National University Bundang Hospital
CHAAMP (CHArlotte Advocate MGUS Project) Internal Pilot Study
Wake Forest University Health Sciences
Leflunomide for the Treatment of High-Risk Smoldering Multiple Myeloma
City of Hope Medical Center
Personalized Vaccine in Treating Patients With Smoldering Multiple Myeloma
M.D. Anderson Cancer Center
Non-chemotherapeutic Interventions for the Improvement of Quality of Life and Immune Function in Patients With Multiple Myeloma
Roswell Park Cancer Institute
Registry for Adults With Plasma Cell Disorders (PCD's)
UNC Lineberger Comprehensive Cancer Center
A Study of a Plant-Based Diet and Dietary Supplements in People With Smoldering Multiple Myeloma (SMM) or Monoclonal Gammopathy of Undetermined Significance (MGUS)
Memorial Sloan Kettering Cancer Center
The Indiana Myeloma Registry
Indiana University
PROFAST
Dana-Farber Cancer Institute
A Study of a Plant-Based Diet in People With Monoclonal Gammopathy of Undetermined Significance (MGUS) or Smoldering Multiple Myeloma (SMM)
Memorial Sloan Kettering Cancer Center
Immunomodulatory Drugs (Lenalidomide With or Without Pomalidomide) in Combination With a Corticosteroid Drug (Dexamethasone) for the Treatment of Multiple Myeloma
Mayo Clinic
LOOMIS
Oxford University Hospitals NHS Trust
Early Detection of Multiple Myeloma to Fight Cancer Disparities: A Screening and Patient Navigation Program
Case Comprehensive Cancer Center
Trial of Combination of Ixazomib and Lenalidomide and Dexamethasone in Smoldering Multiple Myeloma
Dana-Farber Cancer Institute
Screening for AL Amyloidosis in Smoldering Multiple Myeloma
Tufts Medical Center
The TG01 Study With TG01/QS-21 Vaccine in Patients With High-risk Smouldering Multiple Myeloma and Multiple Myeloma
Oslo University Hospital
MODIFY
University College, London
Melphalan and Radiation Therapy Followed By Lenalidomide in Treating Patients Who Are Undergoing Autologous Stem Cell Transplant for Stage I, Stage II, or Stage III Multiple Myeloma
City of Hope Medical Center
Immuno-PRISM (PRecision Intervention Smoldering Myeloma)
Dana-Farber Cancer Institute
ONCO-MRI
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
DEFENCE
Arbeitsgemeinschaft medikamentoese Tumortherapie
Selinexor for the Treatment of Intermediate and High-Risk Smoldering Multiple Myeloma
University of Rochester
OxPLoreD
University of Oxford
Screening to Improve Survival in AL Amyloidosis
Tufts Medical Center
HMvax-Regist
Wake Forest University Health Sciences
ASCENT
International Myeloma Foundation
HO147SMM
Stichting Hemato-Oncologie voor Volwassenen Nederland
Dendritic Cell DKK1 Vaccine for Monoclonal Gammopathy and Stable or Smoldering Myeloma
Case Comprehensive Cancer Center
A Phase II Trial If Nivolumab, Lenalidomide and Dexamethasone in High Risk Smoldering Myeloma
Dana-Farber Cancer Institute